AIMM Therapeutics BV has announced the appointment of Jan de Vries, formerly head of the Novartis Research Institutes for Biomedical Research in Basel, Switzerland, as its new chief executive officer. At Novartis, Dr de Vries was instrumental in developing many drugs including the multiple sclerosis treatment, Gilenya (fingolimod).
Concurrently, AIMM has appointed John Womelsdorf as vice president for business development. Dr Womelsdorf has worked in business development at Optimer Pharmaceuticals Inc, Cyclacel Pharmaceuticals Inc, Johnson & Johnson Inc and the Roche group.
Based in Amsterdam, the Netherlands, AIMM Therapeutics has developed a new antibody technology platform. It announced the appointments on 8 November 2012.
Copyright 2012 Evernow Publishing Ltd